Free Patent/Trademark Report to Commissioner - District Court of Delaware - Delaware

Case 1 :04-cv-00940-JJE, Document 127-2 Filed 05/27/2008 Page 1 of 2
IN THE UNITED STATES DISTRICT COURT {
FOR THE DISTRICT OF DELAWARE
THE PROCTER & GAMBLE COMPANY, ) 5
Plaintiff, J
V' g Civ. Action No. 04-940-JJF
TEVA PHARMACEUTICALS USA, INC., )
Defendant. J
) i
ORDER OF FINAL JUDGMENT ?
This action having come to trial in November 2006 before this Court, Honorable Joseph
1
J. F arnan, Jr., District Judge, presiding, on all remaining issues not previously stipulated to by
the parties pursuant to the Stipulation and Order (D.I. 63) entered by the Court on February 2,
2006 and the Stipulation and Order (D.I. 86) entered by the Court on November 8, 2006;
AND these issues having been tried and the Court having issued its Opinion on February
28, 2008;
NOW THEREFORE, IT IS ORDERED AND ADJUDGED for the reasons set forth in @
this Court’s Opinion dated February 28, 2008, that Final Judgment is entered in favor of the 5
Plaintiff, The Procter & Gamble Company ("Procter &Gamble"), and against the Defendant,
Teva Pharmaceuticals USA, Inc. ("Teva USA"), on Procter &Gamble’s claims that Teva USA
has infringed Claims 4, 16 and 23 of U.S. Patent 5,583,122 ("the ’122 patent");
AND IT IS FURTHER ORDERED AND ADJUDGED that Claims 4, 16, and 23 of the 2
’ 122 patent are valid and enforceable; I l
AND IT IS FURTHER ORDERED that, pursuant to 35 U.S.C. § 271(e)(4)(A), the I J
effective date for any approval of Teva USA’s Abbreviated New Drug Application No. 77-132
1
DB02:6828638.1 1 0529501021 L
l
l

Case 1:04-cv-00940-JJF Document 127-2 Filed 05/27/2008 Page 2 of 2
shall be modified to a date which is not earlier than the date of expiration of the ’ 122 patent,
including any extension of the term of that patent;
AND IT IS FURTHER ORDERED that, pursuant to 35 U.S.C. § 271(e)(4)(B), Teva
USA, its successors-in—interest, officers, agents, servants, attorneys and employees, and those
persons in active concert or participation with any of them who receive actual notice of this
Order by personal service or otherwise, are hereby enjoined from commercially making, using,
offering to sell, or selling within the United States or importing into the United States any
products that infringe the ’ 122 patent, including the 5 mg or 35 mg risedronate sodium tablets for
treatment or prevention of osteoporosis or the 30 mg tablets for treatment of Paget’s disease of
bone, that are the subject of Abbreviated New Drug Application No. 77-132, until the expiration
ofthe ’l22 patent (December I3, 2013), including any extension of the term of that patcnt.
DATED this 9, Q day of 2008. i
E Iinited §2at%/ Iistrict Judge é
DB02;6sza6ss.1 2 O58956.1021